How to Find Key Opinion Leaders by Targeting Several Micro-Influencers Instead of One Big Name

How to find key opinion leaders in medtech starts with a targeting decision most companies get backward. Instead of chasing one big name, the stronger approach is finding three to five smaller, credible voices and building with all of them at once.

That means looking past job titles, past podium appearances, and past the biggest follower counts.

Key Takeaways

• Three to five micro-influencers outperform one big-name KOL, because a single large account's post reads as an obvious paid placement.
• LinkedIn targeting by job title alone misses people, while groups surface specialists such as bariatric surgeons that a title search never reaches.
• A traditional KOL on a podium a couple of times a year is invisible the other 360 days, while a digital opinion leader stays active year-round.
• A KOL who adopted the da Vinci system 10 years ago may have too much brand identity to risk on your startup, so innovators matter more at launch.
• The people who help you at launch usually drop off once you reach the mainstream market, so the list needs revisiting then.

Watch the full episode on YouTube

How to Find Key Opinion Leaders Through Several Micro-Influencers Instead of One Big Name

Finding key opinion leaders in medtech comes down to a volume decision. A single large account posting about your device reads as an obvious paid placement, while three to five smaller, credible voices look organic and natural to a clinical audience.

I covered this on an episode about using LinkedIn ads to attract early adopter surgeons and discover KOLs:

"You're better off finding three to five micro-influencers versus just one big influencer, because you don't know how people are going to take that kind of a post from, let's say, a very large account. It becomes a little bit more obvious, versus when it looks a lot more organic and natural from a smaller account."

One well-known name feels like a shortcut, but it concentrates all the credibility risk in a single post that a clinical audience can spot as sponsored.

Smaller accounts bring a second advantage. On the episode I said they're usually easier to work with, because this is new for them and they're more open to your suggestions.

I also offered a theory about LinkedIn itself, and I flagged that I have no way of proving it.

The platform wants new accounts to grow, so it may push their posts in front of more people than it does for an account with tens of thousands of followers.

You also want more than one person. The ideal scenario is that you test several candidates and ask who is a potential KOL in the making, because the right person today may move upstream as the company grows.

How Does LinkedIn Group Targeting Surface Key Opinion Leaders That Job Titles Miss?

Job title targeting alone misses specialists worth finding, because LinkedIn groups surface people a title search never reaches. The strongest approach combines titles, interests, and the groups specialists belong to, then puts ad budget behind an organic post and watches who engages.

On the same episode, I broke down the targeting approach:

"Think about not only the job titles but interests. So for example, if you're targeting bariatric surgeons and general surgeons, that's a job title you want to look for. Think about also the groups that they fall into, because if you search groups on LinkedIn, you'll find those."

A bariatric surgeon who's active in a relevant LinkedIn group but lists a generic title on their profile never surfaces in a title-only search. The specialty conversation happens in the group, and that's where the targeting signal lives.

The ad strategy starts with an organic post and puts paid ads behind it. I said to let the targeting run for two weeks, and a month works too. Then you watch who engages.

Surgeons who like the post become outbound targets. You can message them to say you noticed they liked a colleague's post and offer more information, or you can send a recording of your demo.

My co-host added a check I like. Audit the followers, because LinkedIn and other tools let you see who follows a candidate, so you can confirm that surgeons, CEOs, or sales leaders matching your target titles are in that audience.

For more on the channel itself, I wrote about social media marketing in healthcare and what works for medtech.

Traditional KOLs Go Invisible 360 Days a Year

A traditional key opinion leader who only shows up at a conference podium a couple of times a year is invisible the rest of the time. Digital opinion leaders fill that gap, and the strongest strategy uses both.

I described a digital opinion leader on the same episode:

"Somebody who may not be on a podium, maybe they're in private practice, maybe they just don't publish a lot, but because of their following, because of their reach, they can persuade people at scale."

That's why I said not every KOL is a digital opinion leader, and not every digital opinion leader is a KOL.

KOLs have a place, and I said they're very important in your strategy. They're great for conferences and the podium. The question is what you do in between.

Say a company attends about five major conferences a year. That leaves most of the calendar empty, and a digital opinion leader is who fills it.

I interviewed Matt Barber, MD, on an episode about finding new orthopaedic technology using LinkedIn. The conversation turned to the old model's blind spot:

"They've also had consultants and key opinion leaders that they got on a podium a couple times a year, and they were influential in that time. They were great speakers, and then 360 days of the year they were completely invisible again."

A company chasing that old model is paying for a couple of days of visibility a year. A company building with several active digital opinion leaders is buying a presence that exists every week the audience pays attention.

Why Do Innovators Matter More Than Established KOLs at Launch?

Innovators matter more at launch because they're willing to take a risk on unproven technology, and established KOLs often aren't. A KOL who adopted the da Vinci system 10 years ago may have built too much brand identity to risk it on your startup.

On the episode I separated two groups people tend to lump together.

Innovators are technology enthusiasts and risk-takers, and you can tell a true innovator because they can see the future with their eyes closed. They get your technology the moment they see it, instead of asking who else is using it.

Early adopters come later, once a company is around 10 to 15 percent of market penetration, and they adopt after seeing initial success. I wrote about the company behind that da Vinci example in Intuitive Surgical's commercial strategy behind da Vinci.

Spot innovators early by looking at their adoption behavior and the content they share. A surgeon who was already sharing other people's posts before yours is a good sign.

You're also in a race against time, because there aren't many of these people. Even a sales team of 10, 20, or 50 people won't shortcut the way to them, and that's where digital marketing helps you scale.

The list expires too. I explained why on the same episode:

"The people you use in this early part of the technology adoption curve to attract innovators, they're not going to be your people that you're using to promote your product when you hit the mainstream market. A lot of times those things change."

The people who love the company at the beginning will probably still use the product. You just won't be taking their calls for product requests and features anymore, and I cover where that change lands in the technology adoption curve in healthcare.

What Does All of This Mean for Medtech Founders?

In my experience working with medtech founders, the search for a KOL usually starts too narrow. Founders look for someone who already has the reputation, when the stronger candidates are often the innovators who haven't been activated yet.

Finding key opinion leaders in medtech is an ongoing targeting exercise that keeps running well past the campaign launch. Treat every candidate list as temporary, and plan to rebuild it when your company reaches the mainstream market.

On the episode I called the technology adoption curve my favorite chart of all time, because it explains the point of running any of this.

In the early market you're focused on finding the people who'll try your technology first, and the targeting exists to find them.

Build the LinkedIn targeting around job titles and groups. Start with several smaller voices instead of one big name. Keep your traditional KOLs for the conferences, and use digital opinion leaders for everything in between.

Keep a short list of candidates instead of a single name, and check each person's earlier posts and shared content for the early signs of adoption.

Then expect the names that matter at launch to change once the market moves past early adopters.

Frequently Asked Questions

How do you find key opinion leaders in medtech?

Target LinkedIn by both job title and relevant groups, since groups surface specialists a title search misses. Build with three to five smaller, credible voices rather than one large account.

A single big-name post reads as an obvious paid placement to a clinical audience. Put ad budget behind an organic post, then watch who engages.

What is a key opinion leader in medtech?

A key opinion leader is a clinician or specialist whose opinion carries weight with their peers on a specific technology or procedure. KOLs typically speak at conferences and publish papers.

In medtech, established KOLs are often unwilling to risk their reputation on an unproven startup. So innovators who use the technology first are frequently the stronger launch candidates.

How do digital opinion leaders differ from traditional KOLs?

A traditional KOL who speaks at a conference a couple of times a year is invisible to the audience the rest of the time. A digital opinion leader influences people online and may not publish or speak at conferences.

A digital opinion leader stays active year-round, which gives a company a consistent presence instead of a couple of brief spikes of visibility.

Do the same KOLs work at launch and at scale?

Usually not. The people who help a company launch are often different from the names that drive adoption in the mainstream market.

Your company, your CEO, and your management team change between the early and mainstream market, and so do the people you work with. So the KOL list needs revisiting once the company moves past the early-adopter stage.

Where Should You Go From Here?

If you're doing this yourself. Read the market engineering framework to see how KOL targeting fits into the broader category and narrative work before a launch.

If you want it engineered with you. MarketCraft takes on a small number of medtech teams each quarter, starting with The Market Engineering Audit. It checks whether your gap sits upstream in the category or downstream in sales.

Listen to the Full Conversations

• Using LinkedIn Ads to Attract Early Adopter Surgeons and Discover KOLs
• How to Find New Orthopaedic Technology Using LinkedIn with Matt Barber MD

Subscribe wherever you listen to podcasts.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry. He works with medtech founders and commercial leaders on market engineering, commercialization strategy, and revenue growth.

Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.